insights_auto
Why is ABVX up 3.74%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
€83.30
arrow_upward
+3.74%(+3.00) 1D
Nov 11, 5:36:13 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€81.15
High
€83.80
Low
€80.65
Mkt. cap
7.22B
Avg. vol.
111.90K
Volume
112.81K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€81.15
High
€83.80
Low
€80.65
Mkt. cap
7.22B
Avg. vol.
111.90K
Volume
112.81K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
Idéal Investisseur
·
5 hours ago
Abivax stock down 26% over the quarter despite its rebound
Investing.com
·
1 day ago
ABIVAX at Guggenheim conference: obefazimod data lift outlook
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteabivax.com